Skip to content

THERAVANCE BIOPHARMA, INC.

TBPH

CIK 0001583107

← back to feed
Revenue (TTM)
$79.27M
+129.6% YoY Q1 Apr 2026
Net Income (TTM)
$39.94M
+1,588.1% YoY Q1 Apr 2026
EPS Diluted (TTM)
$0.78
+1,542.9% YoY Q1 Apr 2026
Gross Margin
95.9%
Q1 Apr 2026
Operating Margin
-41.8%
Q1 Apr 2026
Net Margin
50.4%
Q1 Apr 2026
Free Cash Flow (TTM)
$100.37M
Q1 Apr 2026
Cash
$288.1M
Q1 Apr 2026
Total Debt
$0
Q1 Apr 2026
Shares Outstanding
51.55M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings